Once I have a better understanding of your needs, I'll be happy to assist you in preparing your paper!
| Cohort | Population | Dosing (mg) | Primary Endpoints | Key Secondary Endpoints | |---|---|---|---|---| | (dose‑escalation) | Advanced solid tumours, refractory | 5‑150 mg QD (3 + 3 design) | MTD , DLTs, PK, PD (plasma Ang‑2/VEGF) | ORR, disease control rate (DCR) | | 1B (expansion) | HCC (Child‑Pugh A/B) | RP2D (30 mg QD) | Safety, PK, PD | ORR (RECIST 1.1), PFS, OS | | 1C (expansion) | RCC (clear‑cell, prior VEGF‑TKI) | RP2D (30 mg QD) | Same as 1B | Same as 1B | | 1D (combo) | Advanced solid tumours + anti‑PD‑1 | RP2D + pembrolizumab 200 mg q3w | Safety of combo | ORR, DOR, immune‑related AEs | juy-108